These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 31177425)

  • 1. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study.
    Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA
    J Neurosurg; 2024 Jul; 141(1):72-78. PubMed ID: 38277657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
    Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
    Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
    Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
    Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
    Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
    Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
    J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
    Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
    J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and molecular characteristics of pediatric meningiomas.
    Battu S; Kumar A; Pathak P; Purkait S; Dhawan L; Sharma MC; Suri A; Singh M; Sarkar C; Suri V
    Neuropathology; 2018 Feb; 38(1):22-33. PubMed ID: 28901666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KLF4
    von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
    Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges.
    Okano A; Miyawaki S; Hongo H; Dofuku S; Teranishi Y; Mitsui J; Tanaka M; Shin M; Nakatomi H; Saito N
    Sci Rep; 2021 Mar; 11(1):6987. PubMed ID: 33772057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.
    Saygin İ; Çakir E; Kazaz SN; Güvercin AR; Eyüpoğlu İ; Ustaoğlu MM
    Turk J Med Sci; 2024; 54(4):735-743. PubMed ID: 39295608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of frequent NF2 mutations with spinal location predominance and worse outcomes in psammomatous meningiomas.
    Ren L; Xie Q; Deng J; Chen J; Yu J; Wang D; Wakimoto H; Gong Y; Hua L
    J Neurosurg; 2024 Sep; 141(3):593-601. PubMed ID: 38552238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic analysis of non-neurofibromatosis type 2 meningiomas.
    Parry PV; Engh JA
    Neurosurgery; 2013 Jun; 72(6):N18-9. PubMed ID: 23685513
    [No Abstract]   [Full Text] [Related]  

  • 20. AKT1
    John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.